# US 2020/0399332 A1 · Variant aim > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2020/0399332 A1 - Document ID: US20200399332A1 - Status: Published application - Kind: A1 - Application number: 16/764,755 - Filed: 2018-10-09 - Published: 2020-12-24 - Earliest claimed: 2017-11-16 - Assignees: Toro Miyazaki - Inventors: Toru Miyazaki; Satoko Arai - Web page: https://patentgrep.com/patent/US20200399332A1 ## CPC - C07K 14/4702: {Regulators; Modulating activity} - C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere} - C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression - C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C07K 2319/02: containing a signal sequence - C07K 2319/50: containing protease site - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The present invention relates to the provision of a recombinant AIM that maintains functions, does not multimerize, and is not inactivated by IgM (e.g., a protein containing an amino acid sequence wherein cysteine at amino acid number 168 of the amino acid sequence shown in SEQ ID NO: 1 is substituted with another amino acid, and the like). ## Claims ### Claim 1 A mutant human AIM comprising an amino acid sequence of any one of the following (1) to (5) and having an activity of wild-type human AIM: (1) an amino acid sequence wherein cysteine at amino acid number 168 of the amino acid sequence shown in SEQ ID NO: 1 is substituted with another amino acid, (2) an amino acid sequence wherein cysteine at amino acid number 277 of the amino acid sequence shown in SEQ ID NO: 1 is substituted with another amino acid, (3) an amino acid sequence wherein cysteine at amino acid number 168 of the amino acid sequence shown in SEQ ID NO: 1 is substituted with another amino acid, and an amino acid sequence wherein cysteine at amino acid number 277 of the amino acid sequence shown in SEQ ID NO: 1 is substituted with another amino acid, (4) an amino acid sequence substantially the same as the amino acid sequence of any one of (1) to (3), and cysteines present in the amino acid sequence of any one of (1) to (3) and the substituted another amino acid remain, or (5) an amino acid sequence further comprising deletion, addition, insertion or substitution of one to several amino acids or a combination thereof at a position other than cysteines present in the amino acid sequence of any one of (1) to (3) and the substituted another amino acid. ### Claim 2 (depends on 1) The mutant human AIM according to claim 1, wherein said another amino acid is an amino acid selected from the group consisting of asparagine, glutamine, serine, and threonine. ### Claim 3 (depends on 1) The mutant human AIM according to claim 1, wherein said another amino acid is serine. ### Claim 4 A mutant mouse AIM comprising an amino acid sequence of any one of the following (1) to (3) and having an activity of wild-type mouse AIM: (1) an amino acid sequence wherein cysteine at amino acid number 168 of the amino acid sequence shown in SEQ ID NO: 2 is substituted with another amino acid, (2) an amino acid sequence substantially the same as the amino acid sequence of (1), and cysteines present in the amino acid sequence of (1) and the substituted another amino acid remain, or (3) an amino acid sequence further comprising deletion, addition, insertion or substitution of one to several amino acids or a combination thereof at a position other than cysteines present in the amino acid sequence of (1) and the substituted another amino acid. ### Claim 5 (depends on 4) The mutant mouse AIM according to claim 4, wherein said another amino acid is an amino acid selected from the group consisting of asparagine, glutamine, serine, and threonine. ### Claim 6 (depends on 4) The mutant mouse AIM according to claim 4, wherein said another amino acid is serine. ### Claim 7 (depends on 1, 2, 3, 4, 5, 6) A nucleic acid comprising the base sequence of the following (1) or (2); (1) a base sequence encoding the mutant human AIM according to any one of claim 1 to 3, or (2) a base sequence encoding the mutant mouse AIM according to any one of claims 4 to 6. ### Claim 8 (depends on 7) An expression vector comprising the nucleic acid according to claim 7. ### Claim 9 (depends on 8) A host cell comprising the expression vector according to claim 8. ### Claim 10 (depends on 9) A method for producing a mutant human AIM or a mutant mouse AIM, comprising culturing the host cell according to claim 9. ### Claim 11 (depends on 1) A pharmaceutical composition comprising the mutant human AIM according to claim 1. ### Claim 12 (depends on 2) A pharmaceutical composition comprising the mutant human AIM according to claim 2. ### Claim 13 (depends on 3) A pharmaceutical composition comprising the mutant human AIM according to claim 3. ### Claim 14 (depends on 4) A pharmaceutical composition comprising the mutant mouse AIM according to claim 4. ### Claim 15 (depends on 5) A pharmaceutical composition comprising the mutant mouse AIM according to claim 5. ### Claim 16 (depends on 6) A pharmaceutical composition comprising the mutant mouse AIM according to claim 6.